Skip to main content
BioNumerik Pharmaceuticals, Inc. Home Page

About Us

BioNumerik Pharmaceuticals, Inc. Feature

Board of Directors

BioNumerik’s Board of Directors includes experienced professionals with substantial experience in business and financial operations as well as medical, scientific, and pharmaceutical development expertise.

Steve Carchedi

Board Member; Lead Outside Director; Executive Chairman of Transaction Committee

Mr. Carchedi is currently Chief Executive Officer and President of Cornerstone Pharmaceuticals, an oncology discovery and development company focused on cancer metabolism.  Mr. Carchedi was previously President, Commercial Operations North America of Mallinckrodt Pharmaceuticals, which recently became an independent company after being part of the pharmaceuticals business of Covidien. During his career, Mr. Carchedi has led in the commercialization of multiple oncology products that are on the market today as the standard of care. Prior to joining Mallinckrodt, Mr. Carchedi was the Chief Marketing Officer for General Electric (GE) Healthcare-MDx where he was responsible for leading worldwide marketing for GE's Medical Diagnostics business. Prior to GE Healthcare, Mr. Carchedi held senior commercial leadership positions at Endo Pharmaceuticals, Enzon Pharmaceuticals and McNeil Specialty Pharmaceuticals, a subsidiary of Johnson & Johnson. Mr. Carchedi also held the position of Global Marketing Leader for Johnson & Johnson Oncology, where he led the worldwide product launch of VELCADE® (Bortezomib). Before joining Johnson & Johnson, Mr. Carchedi played a key role in commercializing the oncology portfolio at Eli Lilly & Company, including GEMZAR® (Gemcitabine), and in commercializing leading oncology chemotherapies at Bristol Myers Squibb, including TAXOL® (Paclitaxel) and PARAPLATIN® (Carboplatin). Currently, Mr. Carchedi serves on the Board of Directors of Cornerstone Pharmaceuticals and Sunesis Pharmaceuticals, and on the Strategic Advisory Board for PCAsso Diagnostics LLC.  Mr. Carchedi also previously served as Co-Chair of the BioNJ Personalized Medicine & Diagnostics Committee Counsil (CMOC), as a member of the Ontario Institute of Cancer Research Commercial Committee (OICR) and on Pharmaceutical Industry Board of the American Pediatric Family Foundation. Mr. Carchedi received a B.S. in Marketing from West Chester University and an MBA in Marketing from Drexel University.

Steve Carchedi

Homer L. Pearce, Ph.D.

Board Member

Dr. Pearce recently retired from Eli Lilly & Company where he held leadership positions in cancer drug discovery and development for more than twenty-five years, most recently as Distinguished Research Fellow. Dr. Pearce has been committed to the discovery and development of cancer therapeutics since joining Eli Lilly & Company in 1979. At Eli Lilly, he served in a number of capacities including Vice President, Cancer Research and Clinical Investigation. During his twenty-seven year career, twenty-five investigational drugs entered clinical trials and two new drugs, Gemzar® and Alimta®, were approved for the treatment of a variety of cancers. The recipient of numerous awards throughout his career, Dr. Pearce was most recently named “A Hero of Chemistry” by the American Chemical Society, for his role in the discovery and development of Alimta®, the first drug ever approved for the treatment of malignant pleural mesothelioma. Dr. Pearce is a member of the American Association for Cancer Research, the American Chemical Society and the American Association for the Advancement of Science. Dr. Pearce currently serves as a Board Member, Scientific Advisor, or Business Director to a number of leading research institutions, foundations and biotechnology companies. He received a B.S. from Texas A&M University and his Ph.D. from Harvard University.

Homer L. Pearce, Ph.D.

John W. Yarbro, M.D., Ph.D.

Board Member

Dr. Yarbro is the Founding Editor and Editor Emeritus of Seminars in Oncology, Emeritus Professor of Medicine and a past Chairman of the Department of Oncology of the University of Missouri School of Medicine. Dr. Yarbro retired as Professor of Medicine in 1995 and has been an editor, writer, consultant, and private investor since that time. Dr. Yarbro served two terms as the Chairman of the Panel on Hematologic & Neoplastic Disease and as a Member of the Committee of Revision of the U.S. Pharmacopeia. Dr. Yarbro also served as Vice-Chairman of the American Joint Committee on Cancer, and during his career he has held numerous senior and internationally recognized leadership, administrative and advisory positions with organizations including the American Cancer Society and the American Society of Clinical Oncology. Dr. Yarbro has also served as Associate Director of the National Cancer Institute and a Fulbright Lecturer. Dr. Yarbro received a B.S., summa cum laude, and an M.D. degree from the University of Louisville and a Ph.D. in biochemistry from the University of Minnesota.

John W. Yarbro, M.D., Ph.D.